Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

NCT04642664 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Cholangiocarcinoma
Biomarker
Hepatobiliary Neoplasm

Interventions

DRUG: Apatinib plus Camrelizumab

Sponsor

Peking Union Medical College Hospital